Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
PaperCitations, authors & open-access status
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 117 citations, 2018 year and hybrid oa status.
117
Citations
2018
Year
hybrid
OA Status